Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases $667,000.00 in Stock

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi bought 667,000 shares of Tiziana Life Sciences stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $1.00 per share, for a total transaction of $667,000.00. Following the acquisition, the chief executive officer directly owned 4,472,261 shares of the company’s stock, valued at $4,472,261. The trade was a 17.53% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Tiziana Life Sciences Stock Performance

NASDAQ:TLSA traded up $0.02 on Wednesday, hitting $0.99. 966,207 shares of the stock were exchanged, compared to its average volume of 239,572. The stock has a fifty day moving average of $1.16 and a 200-day moving average of $1.31. Tiziana Life Sciences Ltd has a fifty-two week low of $0.87 and a fifty-two week high of $2.53.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Weiss Ratings downgraded shares of Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Wall Street Zen lowered Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Finally, Zacks Research raised Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Tiziana Life Sciences presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Zhang Financial LLC boosted its stake in shares of Tiziana Life Sciences by 12.0% in the first quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock valued at $131,000 after purchasing an additional 12,000 shares during the period. Marshall Wace LLP increased its stake in Tiziana Life Sciences by 5.2% during the 4th quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock worth $420,000 after buying an additional 14,005 shares during the period. Rachor Investment Advisory Services LLC acquired a new position in Tiziana Life Sciences in the 4th quarter worth $25,000. Cubist Systematic Strategies LLC purchased a new position in Tiziana Life Sciences in the 1st quarter valued at about $25,000. Finally, HRT Financial LP purchased a new position in Tiziana Life Sciences in the 4th quarter valued at about $36,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.